Auris Medical Holding Ltd. (EARS): Price and Financial Metrics
EARS Price/Volume Stats
| Current price | $3.05 | 52-week high | $6.60 |
| Prev. close | $3.10 | 52-week low | $0.73 |
| Day low | $3.00 | Volume | 174,000 |
| Day high | $3.09 | Avg. volume | 3,096,183 |
| 50-day MA | $3.37 | Dividend yield | N/A |
| 200-day MA | $2.86 | Market Cap | 34.82M |
EARS Stock Price Chart Interactive Chart >
Auris Medical Holding Ltd. (EARS) Company Bio
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. The company was founded in 1998 and is based in Zug, Switzerland.
Latest EARS News From Around the Web
Below are the latest news stories about Auris Medical Holding Ltd that investors may wish to consider to help them evaluate EARS as an investment opportunity.
Auris Medical launches new corporate websiteAuris Medical Holding (EARS) announces the launch of its newly-designed corporate website www.aurismedical.com. "...the new website reflects the company’s recent strategic move into RNA therapeutics, while highlighting the exciting prospects for its traditional businesses," CEO Thomas Meyer said.Shares down nearly 1% premarket.Auris had announced plans of its strategic repositioning, last month.... |
Auris Medical Announces Launch of New Corporate WebsiteHamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com. The new website features a streamlined and modern design and also reflects the Company’s recently announced strategic repositioning. “We are proud to present our projects and products a |
Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced addit |
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ TechnologyTreatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission in late 2022 Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal |
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in GermanyHamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; |
EARS Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -10.56% |
| 5-year | -50.41% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 61.73% |
| 2019 | -82.24% |
Loading social stream, please wait...